GlaxoSmithKline

FDA approves GSK’s Breo Ellipta to treat COPD

Friday, May 17, 2013 01:25 PM

The FDA has approved GlaxoSmithKline and Theravance’s Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations. 

More... »

GSK deal aims to grow business in Asia

Tuesday, May 14, 2013 01:30 PM

DKSH's Business Unit Healthcare, a market expansion services provider for healthcare companies seeking to grow their business in Asia, has signed an agreement with GlaxoSmithKline to provide contract sales services in both private clinics and trade channel for its antibiotic product line.

More... »

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Tuesday, May 14, 2013 01:12 PM

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

More... »

JDRF appoints David E. Wheadon as executive vice president of research and advocacy

Thursday, May 9, 2013 12:04 PM

Juvenile Diabetes Research Foundation (JDRF), a global organization funding type 1 diabetes (T1D) research, has appointed David E. Wheadon, M.D., as its new executive vice president of research and advocacy.

More... »

BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

Tuesday, April 30, 2013 08:00 AM

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Thomas W. D'Alonzo to the company's board of directors.

More... »

GSK, Impax Pharmaceuticals terminate collaboration on IPX066

Monday, April 29, 2013 02:25 PM

Impax Pharmaceuticals, the brand products division of Impax Laboratories, and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the U.S. and Taiwan.

More... »

GSK, A*STAR's ICES to develop new medicines for emerging markets

Wednesday, April 10, 2013 09:17 AM

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.\

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

GSK publishes 2012 corporate responsibility report

Wednesday, April 3, 2013 10:18 AM

GlaxoSmithKline has published its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and outlines advances made on this agenda during 2012.

More... »